Abstract:Chromodomain helicase DNA binding protein 5 (CHD5) is a potent tumor suppressor that serves as a master regulator of a tumor-suppressive network. Examination of the role played by CHD5 in a wide range of human cancers is warranted. In this study, we focused on the epigenetic modification and tumor-suppressive role of CHD5 in lung cancer. We measured CHD5 mRNA and protein expression in lung cancer cells, lung cancer tissues, and their corresponding noncancerous lung tissues using real-time PCR and Western blot analysis. We then determined the methylation status of the CHD5 promoter in these samples using methylation-specific sequencing and analyzed CHD5 re-expression in lung cancer cells treated with or without 5-aza-2-deoxycytidine, an inhibitor of DNA methylation. Next, the lung cancer cell clones stably expressing EGFP-CHD5 protein or EGFP protein, respectively, were obtained and the effects of restored CHD5 expression on cell proliferation, colony formation, and tumorigenicity were assessed. CHD5 expression ranged from low to absent in the lung cancer cell lines and tissues examined; the CHD5 promoter was hyperethylated in these samples. Treatment with 5-aza-dC resulted in a localized decrease in methylation density and an increase in CHD5 expression. Clonogenicity and tumor growth were abrogated in A549 and H1299 cells upon restoration of CHD5 expression. A significant reduction in clonogenicity was observed; an average of 47.83±4.6% reduction for A549-EGFP-CHD5 was observed compared to A549-EGFP, and an average of 56.39±5.3% reduction for H1299-EGFP-CHD5 was observed compared to H1299-EGFP. A549-EGFP exhibited an average tumor size of 452.3±36.5mm3, whereas A549-EGFP-CHD5 exhibited an average tumor size of only 57.7±18.5mm3. Thus, our findings indicate that CHD5 is a potential tumor suppressor gene that is inactivated via an epigenetic mechanism in lung cancer.

The Tumor Suppressor Chromodomain Helicase DNA-binding Protein 5 (CHD5) Remodels Nucleosomes by Unwrapping

Chromodomain Helicase DNA Binding Protein 5 Plays a Tumor Suppressor Role in Human Breast Cancer

Epigenetic identification of CHD5 as a critical 1p36.3 tumor suppressor frequently inactivated by promoter methylation in multiple carcinomas

Autoinhibitory elements of the Chd1 remodeler block initiation of twist defects by destabilizing the ATPase motor on the nucleosome

CHD5 is down-regulated through promoter hypermethylation in gastric cancer

CHD1, a Multifaceted Epigenetic Remodeler in Prostate Cancer.

Identification of Residues in Chromodomain Helicase DNA-Binding Protein 1 (Chd1) Required for Coupling ATP Hydrolysis to Nucleosome Sliding

DNA-binding and chromatin localization properties of CHD1

CHD5, a tumor suppressor that is epigenetically silenced in lung cancer

The PHD1 Finger of KDM5B Recognizes Unmodified H3K4 During the Demethylation of Histone H3K4me2/3 by KDM5B

The Chromodomain Helicase DNA-Binding Chromatin Remodelers: Family Traits that Protect from and Promote Cancer

Histone Demethylase Lysine Demethylase 5B in Development and Cancer

The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.

The Zinc-Binding Motif Of Human Recq5 Beta Suppresses The Intrinsic Strand-Annealing Activity Of Its Dexh Helicase Domain And Is Essential For The Helicase Activity Of The Enzyme

CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes

CHD6 promotes broad nucleosome eviction for transcriptional activation in prostate cancer cells

Chromatin remodeling by the CHD7 protein is impaired by mutations that cause human developmental disorders

Tumour-associated missense mutations in the dMi-2 ATPase alters nucleosome remodelling properties in a mutation-specific manner

Sentinels of chromatin: chromodomain helicase DNA-binding proteins in development and disease

Diversity Roles of CHD1L in Normal Cell Function and Tumorigenesis

Molecular characteristics and oncogenic role of CHD family genes: a pan-cancer analysis based on bioinformatic and biological analysis